WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced a series of recently issued patents providing broad composition and method of use claims covering double stranded RNA molecules, called dicer substrate siRNAs (DsiRNAs). These patents have issued over the last several months from the intellectual property licensed by Dicerna from the City of Hope (COH) estate in November 2007.
The newly issued claims provide broad protection for the therapeutic use of DsiRNA oligonucleotides, a technology at the core of Dicerna’s current product pipeline development programs. In their breadth, the issued claims clearly establish the dicer substrate technology as a distinct platform approach to harnessing the RNAi phenomenon in the development of human therapeutic products for multiple indications. The collection of recently issued claims cover composition and method of use type claims that allow an expansive approach to the use of DsiRNAs with minimal restriction on the molecular structure of DsiRNAs; thereby, maximizing the design flexibility in preparing therapeutic molecules.
Help employers find you! Check out all the jobs and post your resume.
